Skip to content
Thursday, 19 November 2026 Today’s Dispatch
Ask
Thu 19 Nov 2026
Painting of an Amsterdam apothecary's laboratory in 1818: an apothecary prepares a medicine beside a large mortar while a customer with a dog watches; through a doorway a man works at the scales in the shop.
Johannes Jelgerhuis, The Distillery of Apothecary A. d’Ailly, 1818. Rijksmuseum, Amsterdam. Wikimedia Commons, public domain (CC0).
Dispatch · II.GA.STRU.01

GLP-1 Drugs Add Spending Faster Than They Save It

In the autumn of 2026 the price of the new obesity and diabetes drugs is being reset in the United States by a Medicare negotiation, a Medicare demonstration, a list-price cut and a falling realised price. The drugs already form one of the largest lines in American pharmacy spending. This Dispatch tests whether that money is drawn from surgery, dialysis and cardiology, and finds that the drugs add spending far faster than they remove it, so that the size of the bill depends mainly on price.

10 November 2026 · 15 min read

In the autumn of 2026 the price of the new obesity and diabetes drugs is being reset in the United States by a Medicare negotiation, a Medicare demonstration, a list-price cut and a falling realised price. The drugs already form one of the largest lines in American pharmacy spending. This Dispatch tests whether that money is drawn from surgery, dialysis and cardiology, and finds that the drugs add spending far faster than they remove it, so that the size of the bill depends mainly on price.

On 4 November 2026 Novo Nordisk reported that US list prices for Wegovy and certain Ozempic products will fall to USD 675 a month from 1 January 2027.1 Six days earlier Eli Lilly reported that its US realised prices fell 7 per cent in the third quarter while US volume rose 41 per cent.2 Glucagon-like peptide-1 (GLP-1) drugs are usually discussed as a medical advance. The documents of 2026 discuss them as a budget line. This Dispatch began from the hypothesis that they move money from surgery, dialysis and cardiology to the pharmacy; the evidence narrows it.

Thesis: GLP-1 drugs have become one of the largest single lines in US prescription-drug spending and add to total health spending far faster than they remove costs from surgery, dialysis or cardiology; the size of that line is therefore set mainly by price, and in 2025 and 2026 the price was set by a small number of decisions taken by two manufacturers and US public payers.

Three tests can falsify it, each on public data:

  • Size. If measured savings in surgery, dialysis and cardiology match 2026 US GLP-1 sales, the thesis fails.
  • Mechanism. If official estimates show health offsets close to drug costs, reallocation beats addition and the thesis fails.
  • Scope. If price and coverage decisions in the US, the UK and India left spending unchanged, the thesis fails.

The price list of autumn 2026

The price of semaglutide in the United States no longer has one value. It has at least six, each set by a different instrument.

The highest is the list price. The Centers for Medicare & Medicaid Services (CMS) gave the 2024 list price of a 30-day supply of Ozempic, Wegovy and Rybelsus as USD 959 when it announced, on 25 November 2025, the negotiated prices that take effect in 2027 under the Inflation Reduction Act.3 The negotiated price for semaglutide is USD 274, about 71 per cent lower. In 2024 Medicare’s gross covered cost for the drug was USD 15.2 billion, for 2.3 million enrollees.3 In February 2026 Novo Nordisk announced that from 1 January 2027 the list price of Wegovy, Ozempic and Rybelsus would be USD 675 a month, a cut of about 50 per cent for Wegovy and 35 per cent for Ozempic.4 The company’s November report confirms the change and states that it is expected to affect 2027 cash flow.1

Below the list sit the cash and demonstration prices. In November 2025 Novo Nordisk cut the self-pay price of injectable Wegovy and Ozempic from USD 499 to USD 349 a month.5 The Wegovy pill is sold for USD 149 to 299 a month by dose.1 The Medicare GLP-1 Bridge, an 18-month demonstration run directly by CMS outside the standard Part D benefit from 1 July 2026 to 31 December 2027, pays USD 245 per 30-day supply for Wegovy, Zepbound and Lilly’s oral drug Foundayo, with a USD 50 monthly copayment for beneficiaries who meet body-mass-index criteria.6 The demonstration replaced an earlier design, the BALANCE model, after too few private insurers agreed to take part.6

The lowest price is outside the United States. Semaglutide’s Indian patent expired on 20 March 2026. Natco Pharma planned a generic injection from 1,290 rupees (about USD 14) a month, against about 10,480 rupees (USD 113) for Novo Nordisk’s Wegovy pen, and about 42 manufacturers were expected to launch products within the year.7

II · THE ENGINES — GALEN

One molecule carries prices that differ by a factor of about seventy.
Monthly price of semaglutide by channel, United States and India, 2024–2027, US dollars
ChannelPrice per monthIn forceSet by
US list price, Ozempic / Wegovy / Rybelsus (as stated by CMS)$9592024Manufacturer
US list price, Wegovy and certain Ozempic products$675From 1 Jan 2027Manufacturer
US self-pay, Wegovy and Ozempic injection$349From 17 Nov 2025Manufacturer
Medicare negotiated price, semaglutide$274From 1 Jan 2027CMS, under the Inflation Reduction Act
Medicare GLP-1 Bridge payment (beneficiary pays $50)$2451 Jul 2026 – 31 Dec 2027CMS demonstration
US self-pay, Wegovy pill, by dose$149–2992026Manufacturer
India, Wegovy pen (₹10,480)$113March 2026Manufacturer
India, generic semaglutide injection, starting price (₹1,290)≈ $14From 20 Mar 2026Generic entrant
Source: CMS via Healthcare Dive (26 Nov 2025); Novo Nordisk Form 6-K (4 Nov 2026); Becker’s (24 Feb 2026); 6abc (ABC) (17 Nov 2025); WTW (Aug 2026); ThePrint/Bloomberg (20 Mar 2026). Rupee prices converted by Titanica at the rate implied by ThePrint (₹10,480 = $113, about ₹92.7 per dollar). Ratio of $959 to ≈ $14 computed by Titanica. List and cash prices are before rebates; net prices paid by insurers are not published. · Exhibit 01 · II.GA.STRU.01

The table mixes gross and net figures, and that is the point it records. The list price is the price on which rebates are calculated; the negotiated and demonstration prices are close to what Medicare actually pays; the commercial net price, after rebates to pharmacy-benefit managers, is not published. Lilly’s quarterly report gives the only direct reading of its direction: a 7 per cent fall in US realised prices in the third quarter of 2026 and a 15 per cent fall worldwide.2 Novo Nordisk attributes a 2 per cent fall in adjusted US sales at constant exchange rates in the first nine months of 2026 to “lower realised prices”, largely offset by volume.1

How large the pharmacy line has become

Lilly’s US sales of Mounjaro in the third quarter of 2026 were USD 5.0 billion and of Zepbound USD 5.3 billion, both drugs based on tirzepatide.2 Novo Nordisk’s US sales of obesity products were DKK 15.3 billion in the same quarter and of GLP-1 diabetes products DKK 21.2 billion.1 At the nine-month average rate reported by Novo Nordisk, about 6.43 kroner to the dollar, the two Novo lines amount to about USD 5.7 billion. The two companies together sold about USD 16 billion of GLP-1 and related drugs in the United States in one quarter, or about USD 64 billion at an annual rate.

These are manufacturers’ net sales, after rebates and discounts, which is the measure closest to what the US health system pays for the drugs before pharmacy and distribution margins. The nearest official comparator is the National Health Expenditure Accounts. CMS put US retail prescription-drug spending in 2024 at USD 467 billion, 8.8 per cent of total health spending of USD 5.28 trillion; that figure is also measured roughly net of manufacturer rebates.8 The comparison crosses two years, 2024 for the denominator and 2026 for the numerator, and therefore overstates the share somewhat. With that caveat, two manufacturers’ GLP-1 sales at the 2026 rate equal about 14 per cent of the 2024 retail drug total and about 1.2 per cent of all health spending.

Retail drug spending grew 7.9 per cent in 2024, after 10.8 per cent in 2023, while hospital care reached USD 1.6 trillion and physician and clinical services USD 1.1 trillion.9 The Drug Channels Institute, analysing the same accounts, notes that the retail drug price index rose only 1.4 per cent in 2024, so that most of the growth came from volume and mix, and that growing GLP-1 demand in Part D contributed to Medicare’s drug-spending growth that year.8 In Medicaid, gross spending on GLP-1 drugs for diabetes and weight loss rose from about USD 1 billion in 2019 to almost USD 9 billion in 2024, according to KFF as reported by Stateline.10

Volume explains most of this. Novo Nordisk reports about 4.1 million US prescriptions of injectable Wegovy and about 3.6 million of the Wegovy pill in the third quarter of 2026, and 5.6 million people worldwide reached with its obesity products, 75 per cent more than a year earlier.1

II · THE ENGINES — GALEN

Two manufacturers’ US GLP-1 sales run at about $64 billion a year.
US net sales of GLP-1 and related drugs, third quarter of 2026, and comparison with 2024 national accounts, US dollars
LineQ3 2026Annual rate
Lilly, Mounjaro, US$5.0 bn≈ $20 bn
Lilly, Zepbound, US$5.3 bn≈ $21 bn
Novo Nordisk, obesity products, US (DKK 15,266 m)≈ $2.4 bn≈ $9.5 bn
Novo Nordisk, GLP-1 diabetes products, US (DKK 21,233 m)≈ $3.3 bn≈ $13.2 bn
Total, two manufacturers≈ $16.0 bn≈ $64 bn
US retail prescription drugs, all products, 2024–$467 bn
Annual rate of the two manufacturers as share of 2024 retail drugs–≈ 14%
Annual rate as share of 2024 national health expenditure ($5.28 tn)–≈ 1.2%
Source: Eli Lilly Form 8-K (29 Oct 2026); Novo Nordisk Form 6-K (4 Nov 2026); CMS National Health Expenditure Accounts via Drug Channels Institute (3 Feb 2026). Kroner converted, annual rates and shares computed by Titanica at Novo Nordisk’s nine-month average rate (DKK 643 per USD 100); quarterly rate multiplied by four. Excludes Foundayo ($184 m in Q3), compounded products and other manufacturers. The shares compare 2026 sales with 2024 totals and overstate the current share. · Exhibit 02 · II.GA.STRU.01

What the surgery, kidney and heart lines show

The reallocation hypothesis names three budget lines from which the money would come. Each has a measurable footprint, and each tells a different story.

Bariatric surgery shows the clearest change. A study presented at the 2026 meeting of the American Society for Metabolic and Bariatric Surgery (ASMBS), using the accreditation database of the American College of Surgeons, found that procedures fell below 200,000 in 2024 for the first time since 2020, a decline of more than 20 per cent from the prior year; the society had counted more than 270,000 procedures in 2023 across several datasets.11 The authors did not study causation. A separate study in JAMA Surgery in March 2026, drawing on electronic health records for nearly 32 million eligible adults, found that the share undergoing bariatric surgery fell from 0.17 per cent in the fourth quarter of 2022 to 0.09 per cent in the third quarter of 2025, a decrease of 46.4 per cent, over the period in which prescriptions of Wegovy and Zepbound rose.12

Dialysis shows a trial effect and, in the series reviewed, no budget effect yet. In the FLOW trial, 3,533 people with type 2 diabetes and chronic kidney disease were followed for a median of 3.4 years; a composite of kidney failure, a sustained halving of kidney function or death from kidney or cardiovascular causes occurred in 18.7 per cent on semaglutide and 23.2 per cent on placebo, a hazard ratio of 0.76.13 The Medicare Payment Advisory Commission puts Medicare spending on outpatient dialysis in 2023 at about USD 8.1 billion, for nearly 262,000 fee-for-service beneficiaries.14 In 2024 Medicare’s gross covered cost for semaglutide alone, at USD 15.2 billion, was almost twice that figure.3 A trial reduction in a composite end point translates into avoided dialysis only over years, and for the subset of patients who would otherwise have reached kidney failure.

Cardiology shows the same pattern. The SELECT trial followed 17,604 adults with overweight or obesity and established cardiovascular disease, without diabetes, for a mean of 40 months. Major adverse cardiovascular events occurred in 6.5 per cent on semaglutide and 8.0 per cent on placebo, a hazard ratio of 0.80; 16.6 per cent of the semaglutide group stopped treatment because of adverse events, against 8.2 per cent on placebo.15 An absolute difference of 1.5 percentage points over 40 months means that, by Titanica’s arithmetic, about 67 people were treated for that period for each event avoided. In FLOW, the 4.5-point difference implies about 22.

II · THE ENGINES — GALEN

Surgery volumes fell; the kidney and heart effects come from trials.
Evidence on the three budget lines GLP-1 drugs are said to displace, United States, 2022–2025
LineMeasured changeKind of evidenceBudget scale
Bariatric surgery> 270,000 procedures (2023) to < 200,000 (2024); share of eligible adults operated −46.4% (Q4 2022 to Q3 2025)Registry and health-record volumes; causation not testedProcedure counts only; no national spending series found
Kidney failure and dialysisComposite kidney end point 23.2% → 18.7% over 3.4 years (HR 0.76); ≈ 22 treated per event avoidedRandomised trial (FLOW), type 2 diabetes with CKDMedicare outpatient dialysis ≈ $8.1 bn (2023)
Cardiovascular eventsMajor events 8.0% → 6.5% over 40 months (HR 0.80); ≈ 67 treated per event avoidedRandomised trial (SELECT), obesity with CVD, no diabetesNo single comparable line
For comparison: semaglutide in Medicare Part D–CMS claims data$15.2 bn gross covered cost (2024)
Source: ASMBS 2026 meeting study via News-Medical (5 May 2026); JAMA Surgery study via Becker’s (16 Mar 2026); FLOW and SELECT trial summaries, American College of Cardiology; MedPAC, Outpatient Dialysis Services Payment System (2025); CMS via Healthcare Dive (26 Nov 2025). Numbers treated per event avoided computed by Titanica as the inverse of the absolute risk difference over each trial’s follow-up. The 2023 and 2024 bariatric counts come from different datasets. · Exhibit 03 · II.GA.STRU.01

The bariatric decline is real and large in proportion; no national series of bariatric spending was found to set against the drug line. The kidney and cardiac effects are established by randomised trials; among the sources reviewed for this Dispatch, no official series shows them in dialysis starts or cardiac admissions at a scale comparable to drug spending.

The arithmetic of offsets

The Congressional Budget Office (CBO) has published the most detailed public estimate of how far savings offset the cost. In October 2024 it estimated that authorising Medicare to cover anti-obesity medications would increase federal spending, on net, by about USD 35 billion from 2026 to 2034.16 Direct federal costs would rise from USD 1.6 billion in 2026 to USD 7.1 billion in 2034; savings from improved health would be less than USD 50 million in 2026, rising to USD 1.0 billion in 2034. Per user, CBO estimated a direct federal cost of about USD 5,600 in 2026, falling to USD 4,300 in 2034, against offsetting savings of about USD 50 rising to USD 650.16 The Committee for a Responsible Federal Budget summarised the totals as USD 38 billion in additional drug spending and USD 3 billion in offsetting health savings over the period.17

II · THE ENGINES — GALEN

Official estimates put health offsets at under a tenth of the drug cost.
Congressional Budget Office estimate of Medicare coverage of anti-obesity medications, 2026–2034, US dollars
Measure202620342026–2034
Direct federal cost of the drugs$1.6 bn$7.1 bn≈ $38 bn
Savings from improved health< $0.05 bn$1.0 bn≈ $3 bn
Net increase in federal spending––≈ $35 bn
Direct cost per user≈ $5,600≈ $4,300–
Offsetting saving per user≈ $50≈ $650–
Offset as share of cost per user≈ 0.9%≈ 15%≈ 8% (totals)
Source: Congressional Budget Office, How Would Authorizing Medicare to Cover Anti-Obesity Medications Affect the Federal Budget? (8 Oct 2024); totals as summarised by the Committee for a Responsible Federal Budget (22 Oct 2024). Shares computed by Titanica. The estimate predates the 2025–2026 price changes and the GLP-1 Bridge, and covers obesity coverage only. · Exhibit 04 · II.GA.STRU.01

The CBO estimate is the official evidence bearing on the mechanism test, and it favours addition over reallocation. Offsets grow with time, as the trials suggest they should, from under 1 per cent of cost per user in the first year to about 15 per cent by the ninth. At no point in the window do they approach the cost of the drugs. The estimate was made before the price cuts of 2025 and 2026. A lower price reduces the cost per user without changing the health savings, so the offset share rises as the price falls: in that sense price, more than health effects, determines the net cost.

The strongest objection

The strongest objection a health economist would raise is that budget windows of nine or ten years are too short for a chronic disease whose complications take decades to arrive. The University of Southern California’s Schaeffer Center estimated in 2023 that Medicare coverage would produce USD 175 billion to 245 billion of medical cost offsets in its first ten years and more than USD 700 billion over thirty, and that the societal value of improved health would approach USD 1 trillion over a decade.18 On this view the pharmacy is buying future hospital savings, and the CBO window records the purchase without the delivery.

The objection is accepted in part. The Schaeffer estimates count offsets and benefits, and the paper states that it does not account for the cost of the treatment itself; it assumes immediate, complete uptake among eligible patients, no discontinuation and lifelong therapy.18 The SELECT trial recorded 16.6 per cent discontinuation for adverse events alone within 40 months.15 Offsets that depend on lifelong adherence are a model result. The trials so far report hazard ratios for composite end points, and national spending series have yet to register them. What the objection establishes is that the long-run balance is unknown and depends on persistence and price. What it does not establish is that the money observed in 2026 is being drawn from surgery, dialysis or cardiology. The thesis is therefore narrowed to the period for which data exist: through 2027, GLP-1 drugs add to health spending, and the net cost moves with price.

Who sets the number

If the size of the line depends on price, the next question for the thesis is who sets the price. The record of 2025 and 2026 shows a short list of actors and instruments, most of which moved the price by tens of per cent.

The first is statute. The Inflation Reduction Act allowed CMS to select semaglutide for negotiation, and the resulting USD 274 price applies to Medicare drug plans from 2027.3 The second is executive action under existing waiver authority: Medicare is not permitted to cover drugs for weight loss as such, and the GLP-1 Bridge pays for them through a demonstration that ends on 31 December 2027.6 The third is agreement between government and manufacturers. Novo Nordisk’s outlook cites lower realised prices “amplified by the MFN agreement” with the US Administration, and Lilly refers to a “voluntary agreement with the U.S. government related to drug pricing and access”.12 The fourth is the manufacturers’ own list and cash pricing: the cut to USD 349 in November 2025, the USD 675 list price from 2027 and the dose-based pill prices.541

The fifth instrument is coverage, and it operates in the other direction. Thirteen state Medicaid programmes cover GLP-1 drugs for obesity in 2026, down from sixteen in 2025, according to Stateline. California, New Hampshire, Pennsylvania and South Carolina eliminated coverage for weight loss because the expense strained state budgets; Michigan restricted eligibility to people with morbid obesity, at an expected saving of USD 240 million; North Carolina dropped coverage in October and reinstated it in December.10

II · THE ENGINES — GALEN

Price and coverage were reset by six decisions between August 2025 and July 2026.
Decisions setting the price or coverage of GLP-1 drugs, United States and United Kingdom, August 2025 – November 2026
DateActorInstrumentDecision
14 Aug 2025Eli LillyUK list priceMounjaro list price raised by up to 170% from 1 Sep 2025; NHS price unchanged
17 Nov 2025Novo NordiskUS self-pay priceWegovy and Ozempic cash price cut from $499 to $349 a month
25 Nov 2025CMSInflation Reduction Act negotiationSemaglutide at $274 per 30 days in Medicare from 2027 (2024 list $959)
24 Feb 2026Novo NordiskUS list priceWegovy, Ozempic and Rybelsus list price to $675 from 1 Jan 2027
2025–2026State Medicaid programmesCoverageProgrammes covering obesity use fall from 16 to 13
1 Jul 2026CMSDemonstration (GLP-1 Bridge)Medicare pays $245 a month, beneficiary $50, until 31 Dec 2027
Q3 2026 (reported 29 Oct)Eli LillyRealised net priceUS realised prices −7%, US volume +41%
Source: Pharmaphorum (14 Aug 2025); 6abc (ABC) (17 Nov 2025); CMS via Healthcare Dive (26 Nov 2025); Becker’s (24 Feb 2026); Stateline via The Lund Report (30 Apr 2026); WTW (Aug 2026); Eli Lilly Form 8-K (29 Oct 2026). The realised-price row records a result reported by the company; the other six are decisions. · Exhibit 05 · II.GA.STRU.01

Each of these decisions was taken by a single manufacturer, federal agency or state government. Together they spread the price paid for injectable semaglutide in the main US channels across a range of almost four to one, from USD 959 to USD 245, within two years. The sources reviewed for this Dispatch show no movement of comparable size in the budget lines the drugs were expected to relieve.

Where the claim holds and where it does not

The claim holds most strongly where three conditions meet: high prices, broad coverage and fast uptake. The United States from 2024 to 2027 meets all three. Medicare’s gross semaglutide cost of USD 15.2 billion in 2024 was recorded before Medicare paid for the drugs for weight loss alone; the Bridge adds that population from July 2026.36 Novo Nordisk states that the Bridge “covers a majority of beneficiaries”.1 Each of the instruments in Exhibit 05 acted on a line already measured in tens of billions of dollars.

The claim weakens where coverage is restricted. The state Medicaid withdrawals show the addition mechanism at work from the other side: when a budget cannot absorb the line, the response recorded by Stateline is to stop paying for the drug.10 Coverage limits keep the line smaller and shift the cost to patients who pay cash, which is the channel that the USD 149 to 349 self-pay prices serve.

The claim changes form where a single buyer negotiates. In the United Kingdom the National Health Service negotiated its own price for Mounjaro; when Lilly raised the UK list price by up to 170 per cent from September 2025, stating that it was aligning the price with other European markets “to ensure fair global contributions to the cost of innovation”, the NHS price was unaffected and private providers bore the change.19 The decision moved private spending, and left the public budget where the earlier negotiation had set it.

The claim fails where the patent has expired. In India, generic semaglutide entered at a starting price of about 1,290 rupees a month, roughly an eighth of the brand’s price there, with dozens of manufacturers preparing launches.7 At that price the drug ceases to be a large budget line, and the question of who controls the price is answered by competition.

Against the three tests, the result is as follows. The narrowed thesis survives the first: annualised US sales of about USD 64 billion far exceed any measured saving, the bariatric decline is counted in procedures, and no official series reviewed shows a comparable fall in dialysis or cardiac spending. The original hypothesis of reallocation fails the same test. The narrowed thesis survives the second: CBO’s official estimate puts offsets at about 8 per cent of the drug cost over nine years, and the long-run model that finds large offsets excludes the drug cost and assumes full adherence. It survives the third with a limit: where price and coverage decisions changed in 2025 and 2026 (Medicare, the Medicaid states, the UK private market, India), the price paid changed with them, and where spending was measured, as in Novo Nordisk’s US sales and Michigan’s estimate, it followed; the full effect of the Bridge and the 2027 prices is not yet in any published series.

The bill after 2027

From 1 January 2027 three of the prices in Exhibit 01 change at once: the Medicare negotiated price takes effect, the US list price falls to USD 675 and the Bridge enters its final year.346 Lilly raised its full-year 2026 revenue guidance to USD 91 to 92 billion on 29 October; Novo Nordisk raised its outlook on 4 November to a range of minus 2 to plus 2 per cent growth in adjusted sales at constant exchange rates, after lower realised prices offset higher volume.21 The two reports describe the same market from opposite ends: one company growing on volume, the other holding sales level as price falls.

The working hypothesis held that whoever controls the price of these drugs controls the health budget of the decade. On the evidence available in November 2026 the drugs have become a line larger than whole categories of care, such as Medicare’s outpatient dialysis. The savings they produce in surgery, kidneys and hearts are real in trials and small in budgets. The price that sets the line’s size fell by up to three-quarters in two years, through decisions taken by two manufacturers, one federal agency and a few state governments. Whether the savings eventually catch up depends on how many patients stay on treatment for decades. Until a national series shows them, the health budget will record GLP-1 drugs as an addition, priced by negotiation.

  1. Novo Nordisk A/S, “Financial report for the period 1 January 2026 to 30 September 2026”, Company Announcement No 65/2026, filed as Form 6-K, 4 November 2026 (company filing). https://www.sec.gov/Archives/edgar/data/0000353278/000162828026069805/caq32026.htm (accessed 10 November 2026) ↩︎
  2. Eli Lilly and Company, “Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress”, filed as Form 8-K, 29 October 2026 (company filing). https://www.sec.gov/Archives/edgar/data/0000059478/000005947826000104/q326lillysalesandearningsp.htm (accessed 10 November 2026) ↩︎
  3. Jonathan Gardner, Healthcare Dive, “CMS sets 2027 Medicare prices for Wegovy, Trelegy and 13 other drugs”, 26 November 2025 (press report of the CMS announcement of 25 November 2025, with CMS table of negotiated prices). https://www.healthcaredive.com/news/medicare-price-negotiation-wegovy-ozempic-trelegy-2027/806578/ (accessed 10 November 2026) ↩︎
  4. Becker’s Hospital Review, “Novo Nordisk to lower list price of Wegovy, Ozempic in 2027”, 24 February 2026 (press report of a Novo Nordisk release). https://www.beckershospitalreview.com/glp-1s/novo-nordisk-to-lower-list-price-of-wegovy-ozempic-in-2027/ (accessed 10 November 2026) ↩︎
  5. 6abc (ABC), “Cash price for popular weight loss drug Wegovy dropping 30%, manufacturer says”, 17 November 2025 (press report). https://6abc.com/post/cash-price-popular-weight-loss-drug-wegovy-dropping-30-manufacturer-says/18165050/ (accessed 10 November 2026) ↩︎
  6. WTW, “Medicare’s GLP-1 Bridge program: What employers need to know”, August 2026 (commentary). https://www.wtwco.com/en-us/insights/2026/08/medicares-glp-1-bridge-program-what-employers-need-to-know (accessed 10 November 2026) ↩︎
  7. Satviki Sanjay, ThePrint, “Dozen drugmakers line up Ozempic copies, triggering price crash in India. Generic GLP-1 Era begins”, 20 March 2026 (press report citing Bloomberg). https://theprint.in/india/dozen-drugmakers-line-up-ozempic-copies-triggering-price-crash-in-india-generic-glp-1-era-begins/2884522 (accessed 10 November 2026) ↩︎
  8. Adam J. Fein, Drug Channels Institute, “Latest CMS Data Reveal Six Trends Reshaping U.S. Drug Spending”, 3 February 2026 (commentary on official CMS National Health Expenditure data). https://www.drugchannels.net/2026/02/latest-cms-data-reveal-six-trends.html (accessed 10 November 2026) ↩︎
  9. Becker’s Hospital Review, “US healthcare spending climbed 7.2% in 2024: 8 things to know”, 14 January 2026 (press report of the CMS Office of the Actuary analysis in Health Affairs). https://www.beckershospitalreview.com/finance/us-healthcare-spending-climbed-7-2-in-2024-8-things-to-know (accessed 10 November 2026) ↩︎
  10. Shalina Chatlani, Stateline, “More states consider dropping GLP-1 weight loss drugs from Medicaid”, 30 April 2026, republished by The Lund Report, 5 May 2026 (press report citing KFF). https://www.thelundreport.org/content/more-states-consider-dropping-glp-1-weight-loss-drugs-medicaid (accessed 10 November 2026) ↩︎
  11. News-Medical, “U.S. bariatric surgery rates drop significantly amid GLP-1 surge”, 5 May 2026 (press report of a study presented at the ASMBS 2026 annual meeting). https://www.news-medical.net/news/20260505/US-bariatric-surgery-rates-drop-significantly-amid-GLP-1-surge.aspx (accessed 10 November 2026) ↩︎
  12. Becker’s Hospital Review, “Bariatric surgery volumes continue falling amid GLP-1 boom”, 16 March 2026 (press report of a study in JAMA Surgery, 4 March 2026). https://www.beckershospitalreview.com/glp-1s/bariatric-surgery-volumes-continue-falling-amid-glp-1-boom/ (accessed 10 November 2026) ↩︎
  13. American College of Cardiology, “Evaluate Renal Function With Semaglutide Once Weekly – FLOW”, trial summary of Perkovic V, Tuttle KR, Rossing P, et al., N Engl J Med 2024;391:109–21 (peer-reviewed, summary). https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2024/05/29/17/23/flow (accessed 10 November 2026) ↩︎
  14. Medicare Payment Advisory Commission, “Outpatient Dialysis Services Payment System”, Payment Basics, revised November 2025 (official). https://www.medpac.gov/wp-content/uploads/2024/10/MedPAC_Payment_Basics_25_dialysis_FINAL_SEC.pdf (accessed 10 November 2026) ↩︎
  15. American College of Cardiology, “Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity – SELECT”, trial summary of Lincoff AM, Brown-Frandsen K, Colhoun HM, et al., N Engl J Med 2023;389:2221–32 (peer-reviewed, summary). https://www.acc.org/latest-in-cardiology/clinical-trials/2023/11/09/15/04/select (accessed 10 November 2026) ↩︎
  16. Congressional Budget Office, “How Would Authorizing Medicare to Cover Anti-Obesity Medications Affect the Federal Budget?”, 8 October 2024 (official). https://www.cbo.gov/publication/60441 (accessed 10 November 2026) ↩︎
  17. Committee for a Responsible Federal Budget, “CBO Estimates Medicare Coverage of Weight-Loss Drugs”, 22 October 2024 (commentary). https://www.crfb.org/blogs/cbo-estimates-medicare-coverage-weight-loss-drugs (accessed 10 November 2026) ↩︎
  18. Alison Sexton Ward, Bryan Tysinger, PhuongGiang Nguyen, Dana Goldman and Darius Lakdawalla, USC Schaeffer Center, “Benefits of Medicare Coverage for Weight Loss Drugs”, 18 April 2023 (analyst estimate, white paper). https://schaeffer.usc.edu/research/benefits-of-medicare-coverage-for-weight-loss-drugs/ (accessed 10 November 2026) ↩︎
  19. Pharmaphorum, “Under pressure from Trump, Lilly hikes Mounjaro prices in UK”, 14 August 2025 (press report). https://pharmaphorum.com/news/under-pressure-trump-lilly-hikes-mounjaro-prices-uk (accessed 10 November 2026) ↩︎
Read through the Method
Context
Two manufacturers' US GLP-1 sales ran at about $64bn a year in Q3 2026; CMS set a $274 Medicare price for semaglutide from 2027, the GLP-1 Bridge pays $245 a month from July 2026, and Novo Nordisk cuts US list prices to $675 from January 2027.
Causes
Rapid volume growth at high prices, Medicare coverage for obesity through a demonstration, and price decisions by manufacturers and public payers, set against trial-level benefits whose budget offsets accrue slowly.
Actors
Novo Nordisk and Eli Lilly as manufacturers; CMS, the Congressional Budget Office and MedPAC as federal agencies; state Medicaid programmes; the UK National Health Service; Indian generic manufacturers; the SELECT and FLOW trial investigators; the USC Schaeffer Center.
Perspectives
Three tests (size, mechanism, scope) are applied; the reallocation hypothesis fails the size test, while the narrowed thesis of addition priced by negotiation passes all three, the third with a limit; the long-horizon offset objection is stated and accepted in part.
Relationships
Opens the Galen Domain. Related: Soma, Pilates Promised Fitness at Nominal Cost. The Reformer Made It Bookable (https://titani.ca/dispatch/pilates-reformer-made-it-bookable/); The Firm, Berkshire Kept Buffett's Rules and Changed the Judge (https://titani.ca/dispatch/berkshire-kept-buffetts-rules-and-changed-the-judge/).

One phenomenon each morning. Free.